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Abstract: Type 1 diabetes (DM1) is associated with loss of skeletal muscle and bone mass 
and may affect body fat stores. This study employs computed tomography (CT) scans to 
assess the body composition of DM1 patients referred for pancreas transplant compared to 
healthy controls. A 1:1 case–control design matched study patients with otherwise healthy 
patients from the trauma database. Matching criteria included age ± 5 years, gender, and 
body mass index (BMI) ± 2kg/m2. Nutrition variables included serum albumin and protein 
levels, BMI, and CT measures of muscle mass and fat stores. There were 22 subjects and 22 
controls (median DM1 duration 24 years). DM1 patients had less muscle mass and less 
subcutaneous fat but no difference in visceral fat. Patients with the greatest muscle deficit 
were those with DM1 greater than 20 years and those younger than age 40. DM1 patients 
maintain similar BMI and protein levels compared to healthy controls but have marked 
deficits of muscle and subcutaneous fat. These results inform the nutritional management of 
DM1 patients and quantify the muscle and fat deficits present in these patients. At highest risk 
are young patients and those with duration of DM1 over 20 years. 
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Introduction
Diabetes mellitus (DM) is a group of metabolic diseases characterized by chronic 
hyperglycemia resulting from defects in insulin secretion, insulin action, or both.1 
Diabetes, both type 1 (DM1) and type 2, treated with insulin therapy can lead to 
weight gain.2 Insulin resistance can lead to accelerated muscle loss, mainly due to 
metabolic and hormonal factors.3 Diabetes and other chronic disease states are 
known to be associated with ongoing loss of skeletal muscle (sarcopenia) and 
bone mass, accompanied by an increase in adipose tissue. These conditions can 
then result in sarcopenic obesity or osteosarcopenic obesity.4
New data is emerging in the field of sarcopenia and sarcopenic obesity in 
current literature. Sarcopenia is described as a loss of skeletal muscle mass and 
function, generally related to aging. Primary sarcopenia is caused by aging, while 
secondary sarcopenia is caused by disuse, long-standing diseases like organ failure, 
malignancy, neurodegenerative diseases, and inadequate nutrition.5 Sarcopenic 
obesity is described as an increase in the fat stores in the body seen concurrently 
with sarcopenia.6–8 Sarcopenia is associated with increased mortality in the elderly, 
in patients with end-stage renal disease on dialysis, and in critically ill patients.9 
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Sarcopenia and sarcopenic obesity are associated with 
poor outcomes in patients with cirrhosis including 
increased organ transplant wait list mortality, post- 
transplant infectious risk, and post-transplant 
mortality.10,11 These morphometric changes have also 
been described in children with chronic disease.12
Multiple techniques have been described to assess obesity 
and sarcopenia including anthropometric measurements such 
as body mass index (BMI), mid-arm circumference, arm skin-
fold thickness; handgrip strength, gait and balance assessment, 
assessment of appendicular skeletal muscle mass or appendi-
cular lean mass using dual-energy X-ray absorptiometry 
(DXA) or bioimpedance analysis in clinical setting. 
Radiologic imaging with computed tomography (CT) or mag-
netic resonance imaging (MRI) are standardized tools for 
assessment of visceral and subcutaneous fat, as well as muscle 
mass. These imaging modalities can easily differentiate fat, 
muscle, and other tissues.13 Currently, CT and MRI are the 
gold standards for evaluation of body composition. They can 
also be used to analyze and trend changes in quantity and 
quality of muscle mass, adipose tissue, and bone.14
This study uses CT scans to objectively assess the body 
composition (muscle and fat stores) of a group of type 
DM1 patients with long-standing disease and to compare 
these findings to non-diabetic, healthy, matched control 
patients. A secondary aim was to compare these differ-
ences to more standard measures of nutrition including 
serum protein measures and BMI.
Research Design and Methods
Data for this study were extracted from a single-center 
transplant database of DM1 patients referred for pancreas 
transplant between 2003 and 2015. Inclusion criteria 
included all patients with DM1 that had CT imaging of 
the abdomen during their evaluation for pancreas trans-
plant. Included cases were stratified by age, gender, BMI, 
and duration of diabetes to include a patient population 
that was representative of the population as a whole. Each 
study patient that met the inclusion criteria was matched to 
a healthy control patient. Additionally, laboratory values 
of total protein, albumin, and hemoglobin A1c were col-
lected and included in the analysis.
Control patients were selected from a trauma database 
in order to perform a 1:1 case–control study design. Each 
anonymous, qualifying non-diabetic control had an injury 
severity score less than 10 and received a screening 
abdominal CT scan at presentation to the emergency 
department. Matching criteria included the control being 
age ± 5 years, BMI ± 2 kg/m2, and the same gender as the 
case.
Sarcopenia was assessed by measurements of total 
psoas muscle area and subcutaneous fat area at L2/L3 
intervertebral space on CT scan. Previous studies have 
shown that core muscle area at approximately 5 cm 
above L4/L5 is the most accurate indicator of total body 
skeletal muscle mass.15–17 Measurements were made at 
L2/L3 since this was approximately 5 cm above L4/L5 
and could be easily located in all cases and controls. Peri- 
nephric fat was measured at the hilum of the kidney. Three 
research assistants, who were trained in reading abdomen 
CT scans, made each measurement blind to the measure-
ments of the other assistants and to the diagnosis and 
outcome of the patient. This was done to establish inter- 
rater reliability. Any measurement that differed by 15% 
from the mean was re-examined until a consensus was 
reached. This occurred in 6 patients. The mean of all 
measurements was used in the analysis to minimize the 
human error of each measurement. Total psoas area, total 
subcutaneous fat, and total perinephric fat were scaled for 
the height of the patient by dividing the measured area 
(in mm2) by the height (in cm) squared. This created the 
psoas area index, subcutaneous fat index, and the peri-
nephric fat index used in the comparison between the 
case and control groups.
To make each measurement, the imaging software was 
set to “soft tissue” and the free hand drawing tool was used. 
To measure the total psoas muscle area, the left and right 
psoas muscles were outlined at the L2/L3 space and the areas 
were summed to get the total area. The subcutaneous fat area 
was obtained by subtracting the area of the outlined abdom-
inal cavity from the area outlined just under the dermis. Since 
the level of the kidney differed for each patient, the measure-
ments were taken at the hilum of each kidney. This was done 
by outlining the kidney and vasculature and subtracting this 
area from the area obtained by outlining Gerota’s fascia. 
Total perinephric fat was calculated by summing the right 
and left perinephric values.18
CT images were viewed and measured using Synapse 
picture archiving and communication system (PACS) soft-
ware (FUJIFILM Holdings America Corporation, Valhalla, 
New York, USA). Data were analyzed using Statistical 
Package for the Social Sciences (IBM SPSS Statistics 26, 
IBM Corporation, Armonk, New York, USA). Group differ-
ences were compared using analysis of variance testing and 
non-parametric testing (chi-square) for continuous and cate-
gorical variables, respectively. Retrospective analysis of de- 
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identified patient data for this study was reviewed and 
approved by the Institutional Review Board of the Indiana 
University School of Medicine. No patient consent was 
required by the board for retrospective analysis of previously 
collected data in compliance with the Declaration of 
Helsinki. Patient data were accessed and managed according 
to the data security and privacy policies of the university. All 
data for this study were collected prior to patient listing for 
organ transplantation. Therefore, this study does not involve 
the donation or transplantation of organs.
Results
There were 22 DM1 subjects and 22 matched controls 
(Table 1). The study had 12 males (54%) and 10 (46%) 
females in each group. Group demographics were similar. 
The median age of the patients was 44 years and ranged 
from 20 to 67 years (controls) and from 15 to 65 years 
(diabetics). The mean duration of DM for study patients 
was 24 years. The median BMI was 25.6kg/m2 (controls) 
and 25.1 kg/m2 (DM1), with the diabetic study patients 
being significantly taller (p=0.04). Laboratory measures of 
nutrition were similar between the study and control 
groups. The mean serum albumin and protein levels were 
3.2g/dL and 6.6g/dL (DM1), and 3.4g/dL and 6.4g/dL 
(control) (p=0.53 and 0.15). DM1 patients did have 
lower median psoas index (4.8) compared to controls 
(5.7) (−18% deficit, p=0.06). Similarly, the DM patients 
had a lower subcutaneous fat index (57.3) compared to 
healthy controls (67.3) (−17% deficit, p=0.20). The visc-
eral fat assessments done by peri-nephric index were also 
lower for DM1 patients but did not reach significance.
Subgroup analysis was performed by duration of DM1, 
gender, age, and BMI. Regarding the length of DM1 
diagnosis, the DM1 patients at all disease durations had 
similar biochemical markers of nutrition compared to con-
trols (Table 2). Sarcopenia was seen in the DM1 patients at 
all disease durations when compared to controls. 
Sarcopenia was markedly more severe in the DM1 patients 
with more than 20 years of disease duration (−16% and 
−12%, versus −34%). There were similar deficits in sub-
cutaneous fat when compared to controls (−24%, −31%, 
and −9%, p=0.29), but not in perinephric fat. Of interest, 
the group with the shortest duration of DM1 had a striking 
56% excess of visceral fat.
Males and females were next analyzed separately 
(Table 3). The groups did not differ for albumin and 
protein. These two groups had similar deficits (compared 
to controls) for both muscle mass and subcutaneous fat 
mass. In assessing visceral fat, the males had a marked 
deficit, while the females had a marked excess. Analysis 
by age showed a marked hypoalbuminemia in patients 
under age 40, as well as the largest deficits in muscle 
mass and subcutaneous fat mass for this age group 
(Table 4). Interestingly, these young diabetics were noted 
to have a 30% excess of visceral fat volume. This appears 
to coincide with the excess of visceral fat seen in patients 
with short duration of disease (+56%). The oldest patient 
group (over age 50 years) was quite dissimilar, with 
a minor muscle mass deficit, but a marked deficit in 
visceral fat (−36%).
The final subgroup analysis is by BMI. This analysis is 
critical because many clinicians use BMI as a marker for 
nutrition. Each subgroup was similar in measured serum 
albumin and protein (Table 5). The BMI group ranging 
from 24 to 28.9kg/m2 experienced much worse sarcopenia 
Table 1 Comparison of Demographics and Nutrition Measures 




Overall (Number) 22 22
Demographics
Years of diabetes (mean, median) 24, 28
Gender: Male 54% 54% 1.00
Age (years, median (range)) 44 (20 to 67) 44 (15 to 65) 0.92
Body mass index (median) 25.6 25.1 1.00
Weight (kg; mean, median) 71, 65 80, 82 0.31
Height (m; mean, median) 1.63, 1.63 1.72, 1.71 0.04
Laboratory measures
Serum albumin (g/dL) 3.4 3.2 0.53
Total protein (g/dL) 6.4 6.6 0.15
Sarcopenia (group 
comparison)
Psoas area index (median)
Grouped comparison 5.7 4.8 0.06
Matched comparison (median   
% difference)
−18%
Measures of body fat (group 
comparison)
Subcutaneous fat index (median)
Grouped comparison 67.3 57.3 0.20
Matched comparison (median   
% difference)
−17%
Perinephric fat index (median)
Grouped comparison 12.5 9.8 0.44
Matched comparison (median   
% difference)
0%
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than the lower and higher groups (−35%, compared to 
−4% and −5%). This group also had the greatest deficit 
in subcutaneous fat and in visceral fat. This group demon-
strated clear evidence of severe sarcopenic obesity. The 
highest BMI group had marked excess of visceral fat and 
deficit of subcutaneous fat, providing an interesting finding 
as to how these obese DM1 patients store this excess fat.
Discussion
Sarcopenia and its implications in modern medicine is an 
emerging field. While in general DM is associated with 
sarcopenia in the elderly, DM1 may cause impaired mus-
cle function and reduced bone density in adolescents, 
leading to osteosarcopenia in the long term. However, 
there are limited studies that describe the nutritional trans-
formation in DM1 patients. In this study, the common 
markers of nutrition such as BMI, serum albumin, and 
total protein were similar between DM1 patients and con-
trols. This indicates that these measures alone are not 
reliable to assess nutritional status. DM1 patients did 
have lower muscle mass, as shown by the 18% deficit 
(p=0.06) compared to controls in their calculated psoas 
index. Similarly, the DM1 patients had a deficit of sub-
cutaneous fat (p=0.20, 17% deficit), but little difference in 
visceral fat. To summarize, DM1 patients had similar 
visceral fat but reduced skeletal muscle and subcutaneous 
fat compared to controls. This further indicates that BMI 
alone cannot be used as an indicator of nutritional status as 
there is differential distribution of fat and muscle mass 
among DM1 patients compared to healthy adults.
Subgroup analysis demonstrated that the groups with 
the greatest muscle deficit were those patients with DM for 
greater than 20 years (−34%), patients younger than age 40 
years (−34%), those with BMI 24.0 to 28.9 (−35%). Large 
deficits in subcutaneous fat were found in patients with 
shorter disease duration (−24%, −31%), females (−24%), 
young patients (−27%), and those with BMI 24.0 to 28.9 
(−24%). The visceral fat was quite different, however. 
Young DM1 patients with a shorter duration of disease 
were found to have an excess of visceral fat (+30%, 
+56%), but not subcutaneous fat. Both men and women 
in this series had similar muscle deficits (−20% vs −18%); 
however, women had much more visceral fat than controls 
(+30%) whereas men did not.
The study is an attempt to quantify the changes in body 
composition and nutritional status that may occur in 
patients with DM1 using objective measures such as mus-
cle mass and adipose tissue distribution. However, there 
are multiple limitations to the study including single insti-
tution, retrospective data analysis, small number of study 
patients, confounding factors that can affect DM1 (such as 
treatment of DM), exercise and lifestyle habits of patients, 
and coexistent medical conditions other than DM1 alone. 
More studies are needed to clearly understand these phe-
nomena of sarcopenia and sarcopenic obesity in patients 
with DM1, but this study does demonstrate striking differ-
ences which support the need for further study.
In conclusion, DM1 is associated with loss of skeletal 
muscle mass and may affect body fat stores. While DM1 
patients maintain similar BMI and serum protein levels 
when compared to healthy controls, they experience sar-
copenic obesity as evidenced by reduced muscle mass and 
increased fat stores. These important morphologic changes 
in body composition are missed if the clinician simply 
Table 2 Comparison of Nutrition Measures for Patients with 
Type I Diabetes and Healthy Controls, Stratified by Duration of 
Diabetes
Controls Diabetic Patients: Years of 
Diabetes
p-value*
1 to 10 10 to 20 > 20
22 7 7 8
Laboratory 
measures
Serum albumin (g/dL) 3.4 2.7 3.3 3.3 0.64
Total protein (g/dL) 6.4 6.7 6.0 7.0 0.69
Sarcopenia (group 
comparison)
Psoas area index 
(median)
Grouped comparison 5.7 4.1 5.3 4.6 0.57
Matched comparison 
(median % difference)
−16% −12% −34% 0.52
Measures of body 
fat (group 
comparison)
Subcutaneous fat index 
(median)
Grouped comparison 67.3 58.6 71.4 54.7 0.19
Matched comparison 
(median % difference)
−24% −31% −9% 0.29
Perinephric fat index 
(median)
Grouped comparison 12.5 8.0 13.3 9.5 0.17
Matched comparison 
(median % difference)
56% −4% 13% 0.80
Note: *For difference among years of diabetes groups.
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Table 3 Comparison of Nutrition Measures for Patients with Type I Diabetes and Healthy Control Patients, Stratified by Gender
Males Females
Control Diabetic p-value* Control Diabetic p-value*
12 12 10 10
Laboratory measures
Serum albumin (g/dL) 3.2 3.4 0.68 3.6 2.9 0.20
Total protein (g/dL) 5.9 6.8 0.17 6.7 6.6 0.58
Sarcopenia (group comparison)
Psoas area index (median)
Grouped comparison 6.2 5.2 0.12 4.6 4.0 0.19
Matched comparison (median % difference) −20% −18%
Measures of body fat (group comparison)
Subcutaneous fat index (median)
Grouped comparison 67.3 54.7 0.34 58.2 61.8 0.37
Matched comparison (median % difference) −13% −24%
Perinephric fat index (median)
Grouped comparison 15.6 10.9 0.21 6.1 7.2 0.58
Matched comparison (median % difference) −24% 30%
Note: *For difference within gender groups.
Table 4 Comparison of Nutrition Measures for Patients with Type I Diabetes and Healthy Controls, Stratified by Patient Age
Subject Age
Up to 40 Years 40 to 49 Years 50 Years and Older
Control Diabetic p-value Control Diabetic p-value Control Diabetic p-value
6 6 9 9 7 7
Laboratory measures
Serum albumin (g/dL) 4.1 2.9 0.32 3.2 3.3 0.84 3.6 3.8 0.84
Total protein (g/dL) 7.1 6.3 0.88 6.2 6.1 0.27 6.3 7.4 0.17
Sarcopenia (group comparison)
Psoas area index (median)
Grouped comparison 5.3 4.3 0.36 5.9 4.4 0.15 4.9 4.9 0.51
Matched comparison (median % 
difference)
−34% −19% −12%
Measures of body fat (group 
comparison)
Subcutaneous fat index (median)
Grouped comparison 50.7 54.4 0.50 67.0 56.1 0.51 68.7 60.6 0.37
Matched comparison (median % 
difference)
−27% −6% −14%
Perinephric fat index (median)
Grouped comparison 8.9 7.4 0.74 8.8 10.3 0.72 16.4 17.1 0.32
Matched comparison (median % 
difference)
30% 2% −36%
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follows the patient’s weight and body mass index. Even 
adding an analysis of serum albumin and protein fails to 
distinguish these changes in this population at high-risk for 
co-morbidities. Patients at highest risk for these changes 
appear to be those who are younger and have a longer 
duration of DM1.
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